Versailles, KY, United States of America

Martin J Jacobs

USPTO Granted Patents = 16 (Patent Applications = 1)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 61(Granted Patents)

Location History:

West Chester, PA (US) (2002 - 2014)
Versailles, KY (US) (2015 - 2020)

Company Filing History:

Years Active: 2002-2020

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10632119 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor (2020-04-28),

2. 10150772 - Crystalline forms of PARP inhibitors (2018-12-11),

3. 10111872 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor (2018-10-30),

4. 9987281 - Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor (2018-06-05),

5. 9718810 - Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor (2017-08-01),

6. 9623026 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor (2017-04-18),

7. 9353097 - Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor (2016-05-31),

8. 9339502 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor (2016-05-17),

9. 9132128 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor (2015-09-15),

10. 8633314 - Forms of a multicyclic compound (2014-01-21),

11. 8513272 - Forms of a fused pyrrolocarbazole compound (2013-08-20),

12. 7749540 - Compositions comprising modafinil compounds (2010-07-06),

13. 7704975 - Modafinil compound and cyclodextrin mixtures (2010-04-27),

14. 7141555 - Modafinil compound and cyclodextrin mixtures (2006-11-28),

15. 6919378 - Pharmaceutical solutions of modafinil compounds (2005-07-19),

Title: The Innovative Contributions of Martin J. Jacobs

Introduction: Martin J. Jacobs, an accomplished inventor based in Versailles, KY, has made significant strides in the field of pharmaceuticals. Holding a total of 16 patents, Jacobs has developed groundbreaking compounds that target critical pathways involved in various proliferative disorders.

Latest Patents: Among his latest innovations is the patent for a fused bicyclic 2,4-diaminopyrimidine derivative, which acts as a dual inhibitor of anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK). This compound, represented by a specific formula, has shown promise in treating proliferative disorders. Additionally, Jacobs has developed crystalline forms of PARP inhibitors, specifically 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, which includes both salt forms and free base forms.

Career Highlights: Throughout his career, Martin J. Jacobs has worked for notable companies such as Cephalon, Inc. and Ignyta, Inc. His expertise in pharmacology and drug development has led to significant advancements in therapeutic options available for various medical conditions.

Collaborations: Jacobs has collaborated with talented professionals throughout his career, including Laurent D. Courvoisier and Stephen Bierlmaier. These collaborations have played a vital role in facilitating innovation and enhancing the efficacy of his inventions.

Conclusion: Martin J. Jacobs stands out as a remarkable inventor whose contributions have the potential to impact the treatment of proliferative disorders. With his extensive patent portfolio and collaborative efforts, Jacobs continues to push the boundaries of pharmaceutical science, paving the way for future innovations in health care.

This text is generated by artificial intelligence and may not be accurate.